StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
BHST$3.70-4.15%
Fair $3.70+0.0%

BHST

BioHarvest Sciences Inc. Common Stock

Consumer Defensive / Packaged FoodsNasdaqGM

$3.70

-0.16 (-4.15%)

Fairly Valued+0.0%Fair Value $3.70Fund rank 29/100 · Data gapFallback financials|
SA 24/D
F-Score: 5/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 22%

FCF escenarios

weak_data · normalized FCF $-9.6M · quality 58.3/100

Data gap 29/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 29/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

24/100

D

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -43.8%, below the 5% threshold
Thesis & Journal · BHSTLocal privado en este navegador · BioHarvest Sciences Inc. Common Stock
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$84M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-43.8%

↓

Gross Margin

59.3%

↑

Debt/Equity

0.55

↑
52-Week Range$4
$4$13

TradingView lightweight chart

BHST price, volumen y niveles de valoración

Último $3.700Periodo -63.5%
Fair value: $3.700

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+84.5%

FCF CAGR

—

FCF margin

-27.8%

FCF / Net income

0.86x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $34.5M · net income $-11.1M · FCF $-9.6M

2022-FY → 2025-FY

Gross margin

59.3%+37.2% pts

Operating margin

-16.2%+176.9% pts

Net margin

-32.3%+172.1% pts

FCF margin

-27.8%+163.2% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$34.5M$34.5M$25.2M$12.7M$5.5M
Net Income$-11.1M$-11.1M$-12.9M$-12.6M$-11.2M
EBITDA$-6.7M$-6.7M$-6.9M$-9.8M$-9.1M
EPS-0.60-0.60-0.80-0.93-0.70
Gross Margin59.3%59.3%55.4%44.5%22.2%
Operating Margin-16.2%-16.2%-27.7%-78.6%-193.0%
Net Margin-32.3%-32.3%-51.3%-99.1%-204.4%
Balance Sheet
Debt/Equity0.550.5510.39-1.50-1.78
Current Ratio3.973.97———
Cash Flow
Free Cash Flow$-9.6M$-9.6M$-9.5M$-10.0M$-10.5M
Returns
ROE-43.8%-43.8%-970.9%84.6%189.5%
Valuation
P/B2.682.6876.46——
Growth & Yield
Revenue Growth37.0%37.0%98.8%130.5%—
EPS Growth25.0%25.0%14.0%-32.9%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -40.9%

Total return

-40.9%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.80 → -0.60

Residual

-40.9%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-40.9%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.